A Phase 4 interventional study of Travoprost 0.004% in Open-Angle Glaucoma and Ocular Hypertension, sponsored by Alcon Research. Completed. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-19.
Sponsored by Alcon Research (part of Alcon) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 46 studies testing travoprost in Glaucoma, Open-Angle — 2 open to participants now, 3 under way, 1 of them phase 3. Travoprost · Glaucoma, Open-Angle.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, this one is the 13th largest by enrollment of the 45 interventional ones that give a count, is one of 9 that started in 2011, is one of 22 in phase 4, and was the 33rd registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →2 of the 46 studies testing travoprost in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:
Jonathon Myers · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Travoprost: first FDA approval 2001 (TRAVATAN), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
46 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 9 started in 2011.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 202 is above the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 135 across the 45 interventional studies. Of the 43 that completed or were terminated, 23 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
39 of 46 have an industry lead sponsor. The 10 most frequent:
This study is registered under Alcon Research, one of the names counted as Alcon. Under that name alone:
Alcon Research is the lead sponsor of 624 studies on the registry; 9 are open to participants now.
Of its 112 completed or terminated interventional studies of FDA-regulated products, 102 (91%) have results posted.
126 studies in Glaucoma, Open-Angle by Alcon: 1 open now, 1 under way, none of them phase 3. Of 121 finished, 58 (48%) have results posted.
Among the 126 studies in Glaucoma, Open-Angle by Alcon, this one is the 45th largest by enrollment of the 112 interventional ones that give a count, is one of 22 that started in 2011, is one of 31 in phase 4, and was the 83rd registered.
Alcon’s Glaucoma, Open-Angle studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 46 studies testing travoprost in Glaucoma, Open-Angle, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Alcon’s 126 in Glaucoma, Open-Angle:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the efficacy and tolerability of TRAVATAN® Solution without benzalkonium chloride (BAK) in patients previously on latanoprost 0.005% or bimatoprost 0.01% ophthalmic solution monotherapy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Travoprost 0.004%, 1 drop self-administered to the study eye(s) once daily, every evening at around 8:00 pm, for 12 weeks
Drug: Travoprost 0.004%
Travoprost 0.004% without benzalkonium chloride (BAK), containing Polyquad (PQ) preservative
Also known as: TRAVATAN® BAK-free
Mean Change in Intraocular Pressure (IOP) at 12 Weeks From Prior Therapy (Baseline)
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.
Time frame: Baseline, Week 12
Percentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.
Time frame: Week 12
Subjects were recruited from 15 investigative sites located in Europe: Belgium (2); Spain (6); Italy (4); Sweden (3).
| Milestone | TRAVATAN® BAK-free |
|---|---|
| Started | 199 |
| Completed | 179 |
| Not completed | 20 |
| Withdrew: Adverse event | 10 |
| Withdrew: Personal reasons | 4 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Inability to follow instructions | 2 |
| Withdrew: Other | 2 |
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). A more negative change indicates a greater amount of improvement. One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.
| millimeters mercury (mmHg) | TRAVATAN® BAK-free |
|---|---|
| Baseline | 17.0 ± 3.3 |
| Change from Baseline at Week 12 (n=178) | -1.16 ± 2.65 |
IOP (fluid pressure inside the eye) was measured by Goldmann applanation tonometry. A higher IOP can be a greater risk for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye was chosen as the study eye, and only data from the study eye were used for the efficacy analysis.
| Percentage of participants | TRAVATAN® BAK-free |
|---|---|
| Percentage of Patients With Target IOP (≤18 mmHg) at 12 Weeks | 81.2 |
Collected over Adverse event data were collected and reported in the eCRF at each visit from time of first drug instillation to Week 12. Adverse events were collected for the duration of the study (1 year, 2 months).. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TRAVATAN® BAK-free | — | 4/199 (2%) | 0/199 (0%) |
| Event | TRAVATAN® BAK-free |
|---|---|
| Upper gastrointestinal hemmorhageGastrointestinal disorders | 1/199 |
| Pneumonia pneumococcalInfections and infestations | 1/199 |
| Respiratory tract infectionInfections and infestations | 1/199 |
| CholelithiasisHepatobiliary disorders | 1/199 |
This reporting group includes all subjects who instilled at least one dose of the test article
| Age, Continuous(years) | TRAVATAN® BAK-free |
|---|---|
| Mean | 66.6 ± 11.7 |
| Sex: Female, Male(Participants) | TRAVATAN® BAK-free |
|---|---|
| Female | 117 |
| Male | 82 |
No study locations are listed for this record.
The record gives a start of Dec 2011, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in May 2014, 1 year 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Travoprost